See Local News
Get Balanced News From Your U.S. State.
See Local News
See all locals

It's time for over-the-counter Ozempic

Posted on AllSides May 22nd, 2024
From The Right

The new insulin-stimulating weight-loss drugs semaglutide and tirzepatide appear impressive. Studies suggest they help people shed pounds, reduce the likelihood of heart attacks and strokes, and may even treat kidney problems, HIV-related liver disease, alcoholism, and other maladies. It is easy to see why semaglutide was the top-selling drug in the United States in 2023 ($38.6 billion in sales), with tirzepatide coming in eighth ($13.2 billion). Affordability is a problem, though. Novo Nordisk markets semaglutide as Ozempic, Wegovy, and Rybelsus. Eli Lilly markets tirzepatide as Mounjaro and Zepbound. Each company...

Read full story
Some content from this outlet may be limited or behind a paywall.

More News about Public Health from the Left, Center and Right

From the Left

From the Center

From the Right